Strong Fourth Quarter Boosts Medtronic's Stock Amid Mixed Analyst Opinions

Medtronic’s Recent Financial Performance and Market Movements

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has recently reported strong financial results, leading to notable movements in its stock performance.

Financial Highlights

In the fourth quarter of fiscal year 2026, Medtronic reported revenue of $9.8 billion, marking a 9.9% increase year-over-year. The company’s non-GAAP diluted earnings per share (EPS) stood at $1.55, slightly surpassing analyst expectations of $1.54. CEO Geoff Martha highlighted this as the strongest annual top-line growth in a decade, attributing it to disciplined execution and operational rigor.

A significant contributor to this growth was the Cardiac Ablation Solutions segment, which saw a remarkable 78% increase in global revenue, including a 124% surge in the United States.

Analyst Perspectives

Following these results, TD Cowen reiterated a ‘Buy’ rating for Medtronic, setting a price target of $119.00. The firm noted that the revenue growth was driven by the Cardiovascular segment, which experienced a 10.1% year-over-year organic increase.

Conversely, Needham adjusted its price target for Medtronic to $101 from $120, maintaining a ‘Buy’ rating. The adjustment was based on peer multiples, despite the company’s strong quarterly performance.

Institutional Investments

Dimensional Fund Advisors LP increased its stake in Medtronic by 1.5% during the first quarter, adding 112,976 shares to hold a total of 7.52 million shares valued at approximately $651.2 million.

On the other hand, Chemung Canal Trust Co. reduced its position in Medtronic by 24.2% in the same period, selling 16,261 shares and retaining 50,957 shares valued at about $4.4 million.

Stock Performance

As of July 24, 2026, Medtronic’s stock price stood at $83.21, reflecting a 0.41% increase from the previous close. The stock’s performance has been influenced by the company’s strong financial results and varying analyst opinions.

Conclusion

Medtronic’s recent financial performance underscores its robust position in the medical equipment and services industry. While the company has achieved significant growth, differing analyst perspectives and institutional investment decisions highlight the complexities investors face in evaluating its stock.